Cl.[I:2][C:3]1[C:11]2[C:6](=[N:7][CH:8]=[N:9][C:10]=2[NH2:12])[N:5]([CH:13]2[CH2:17][CH2:16][NH:15][CH2:14]2)[N:4]=1.Br[CH2:19][CH2:20][O:21][CH3:22].C(=O)([O-])[O-].[K+].[K+]>CN(C)C=O.[I-].[K+]>[I:2][C:3]1[C:11]2[C:6](=[N:7][CH:8]=[N:9][C:10]=2[NH2:12])[N:5]([CH:13]2[CH2:17][CH2:16][N:15]([CH2:19][CH2:20][O:21][CH3:22])[CH2:14]2)[N:4]=1To a solution of rac-3-iodo-1-tetrahydro-1H-3-pyrrolyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine mono hydrochloride (0.350 g, 1.09 mmol) in N,N-dimethylformamide (10 mL) was added 2-bromoethylmethyl ether (0.159 g, 0.11 mL, 1.15 mmol), potassium carbonate (0.462 g, 3.34 mmol), and potassium iodide (0.008 g, 0.05 mmol). The reaction mixture stirred at 65° C. for 18 h and then additional 2-bromoethylmethyl ether (0.066 g, 0.040 mL, 0.48 mmol), potassium carbonate (0.130 g, 0.940 mmol), and potassium iodide (0.008 g, 0.05 mmol) were added. The reaction mixture was stirred for an additional 18 h and was then concentrated. The residue was partitioned between dichloromethane (10 mL) and water (10 mL). The organic phase was separated, washed with brine, dried over anhydrous magnesium sulfate, filtered, and concentrated to afford rac-3-iodo-1-[1-(2-methoxyethyl)tetrahydro-1H-3-pyrrolyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine as a yellow solid (0.313 g, 84%) which was used in subsequent reactions without further purification. RP-HPLC Rt 5.089 min, 80% purity (5% to 85% acetonitrile/0.1M aqueous ammonium acetate, buffered to pH 4.5, over 20 min at 1 mL/min; λ=254 nm; Deltapak C18, 300 Å, 5 μm, 150×3.9 mm column); m/z 389 (MH+).
読み込み中…
